姑息性长期腹腔引流管对比大量腹腔穿刺放液治疗肝硬化继发难治性腹水:确证性随机对照试验方案(REDUCe2研究)
REDUCe2是一项在英格兰、苏格兰和威尔士开展的实用性、多中心、开放标签、混合方法、优效性随机对照试验,计划纳入310例肝硬化继发难治性腹水且不适合肝移植或经颈静脉肝内门体分流术的患者,按1:1随机接受长期腹腔引流管或继续标准治疗(大量腹腔穿刺放液)。主要结局为12周时采用短式肝病生活质量问卷评估的肝脏特异性健康相关生活质量。
要点
- REDUCe2为实用性多中心开放标签优效性随机对照试验,计划纳入310例患者,每组155例。
- 研究对象为肝硬化继发难治性腹水且不适合肝移植或经颈静脉肝内门体分流术的患者。
- 主要结局为12周时短式肝病生活质量问卷评估的肝脏特异性健康相关生活质量。
核心结论
- REDUCe2研究旨在评估姑息性长期腹腔引流管对肝硬化继发难治性腹水患者健康相关生活质量的影响,并有望为优化和改善难治性腹水的姑息治疗提供高质量证据。
研究设计与样本
- REDUCe2是一项在英格兰、苏格兰和威尔士开展的实用性、多中心、开放标签、混合方法、优效性随机对照试验。
- 计划纳入310例肝硬化继发难治性腹水且不适合肝移植或经颈静脉肝内门体分流术的患者,按1:1随机接受长期腹腔引流管或继续标准治疗(大量腹腔穿刺放液),每组155例。
- 两臂均进行为期12周、每两周一次的家庭研究访视。
- 主要结局为12周时采用短式肝病生活质量问卷评估的肝脏特异性健康相关生活质量。
主要发现
- REDUCe2为正在进行的试验方案,原文未报告研究结果。
关键数值与推荐
- 主要结局为12周时短式肝病生活质量问卷评估的肝脏特异性健康相关生活质量。
- 次要结局包括症状负担(腹水问卷)、健康效用(EQ-5D-5L工具)、照护者工作量(照护者角色与责任量表-CRRS问卷)、安全性(包括感染、急性肾损伤及其他临床结局)、卫生资源利用以及患者、照护者和医疗专业人员对干预的可接受性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ascites remains the most common complication of cirrhosis and a frequent reason for hospitalisation in advanced chronic liver disease (ACLD). Ascites is associated with significant symptom burden, caregiver workload and poor health-related quality of life (HRQoL). Once refractory to treatment, median survival is poor. Many with refractory ascites (RA) will neither receive a transjugular intrahepatic portosystemic shunt (TIPS) nor a liver transplant. Palliative care remains underutilised and evidence-based interventions focused on improving HRQoL are clearly needed. The standard of care for RA is repeated hospital ascites drainage with large volume paracentesis (LVP). Our earlier feasibility randomised controlled trial (RCT) (REDUCe) showed acceptability of palliative tunnelled long-term abdominal drains (LTADs), as well as preliminary evidence of safety and efficacy. The current REDUCe2 trial is a definitive national study designed to assess the impact of palliative LTADs on HRQoL in patients with RA due to ACLD. METHODS/DESIGN: The REDUCe2 study is a pragmatic, multicentre, open-label, mixed-methods, superiority RCT being conducted in England, Scotland and Wales. Patients with RA secondary to ACLD who are ineligible for a liver transplant or TIPS will be randomised 1:1 to receive a LTAD or continue the current standard of care (LVP). Fortnightly home research visits will be conducted for 12 weeks in both arms. The primary outcome will be liver specific HRQoL assessed at 12 weeks using the Short Form Liver Disease Quality of Life questionnaire (SFLDQoL). Secondary outcomes include assessment of symptom burden (Ascites Questionnaire), health utilities (EQ-5D-5L tool), caregiver workload (Caregiver Roles and Responsibilities Scale-CRRS questionnaire), safety (including infection, acute kidney injury and other clinical outcomes), health resource utilisation and acceptability of the intervention by patients, caregivers and healthcare professionals. We aim to recruit a total of 310 patients (155 in each arm). DISCUSSION: Effective palliative care provision remains an unmet need in ACLD. The REDUCe2 study, the largest palliative interventional trial in the UK, aims to address this inequity for this vulnerable and underserved cohort. It has the potential to generate high quality evidence to optimise and enhance palliative care in RA. TRIAL REGISTRATION: ISRCTN26993825, date registered: 15/08/2022.
引用
- Haddadin Y, Anagnostopoulou V, Bremner S, et al. Palliative long-term abdominal drains vs. large volume paracentesis for refractory ascites secondary to cirrhosis: protocol for a definitive randomised controlled trial (REDUCe2 study). Trials. 2025. PMID: 40468365. doi:10.1186/s13063-025-08873-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。